期刊文献+

SALL4、OCT4、C-kit在精原细胞瘤中的表达观察

Expression of SALL4,OCT4 and C-kit in the Seminoma
下载PDF
导出
摘要 目的:观察SALL4、OCT4、C-kit在精原细胞瘤中的表达,探讨其在该瘤病理诊断中的意义。方法:选取68例精原细胞瘤和20例病理形态相似的非精原细胞性肿瘤的术后标本,应用常规病理学技术及免疫组化Polink-2HRP染色系统检测SALL4、OCT4、C-kit的表达,并观察分析其与临床病理形态特征的关系。结果:SALL4、OCT4、C-kit在68例精原细胞瘤中的表达率分别为100%(68/68)、91.2%(62/68)、95.5%(65/68);在20例非精原细胞性肿瘤中的表达率分别为35%(7/20)、20%(4/20)、25%(5/20);SALL4、OCT4、C-kit在精原细胞瘤中的表达明显高于非精原细胞性肿瘤(P<0.05),差异有统计学意义。结论:SALL4在精原细胞瘤中的表达具有较高的敏感性,协同OCT4、C-kit使用,对其病理诊断具有重要价值。 Objective: To observe the expression of SALL4,OCT4 and C-kit in the seminoma,and to explore its significance in the diagnosis of the tumor. Methods: Postoperative samples of 68 seminoma and 20 non-seminoma with similar Pathologic morphology were selected. The expression of SALL4,OCT4 and C-kit were detected by routine pathological technique and immunohistochemical Polink-2HRP staining system. To observe and analyze the relationship between the clinical features and pathological characteristics. The relationship between the expressions and the clinical pathological morphological features was observed and analyzed. Results: The expression rates of SALL4,OCT4 and C-kit in 68 cases seminomas were 100%( 68 /68),91. 2%( 62 /68) and 95. 5%( 65 /68),respectively. the expression rates in 20 cases of non-seminomas were 35%( 7 /20),20%( 4 /20),25%( 5 /20),respectively; The expression of SALL4,OCT4 and C-kit in the seminomas was significantly higher than that in the non-seminomas. The difference was statistically significant( P〈0. 05). Conclusion: The expression of SALL4 in the seminoma is highly sensitive. It is of great value in the pathological diagnosis if it is used with OCT4 and C-kit.
出处 《赣南医学院学报》 2016年第6期876-879,共4页 JOURNAL OF GANNAN MEDICAL UNIVERSITY
基金 江西省教育厅科学技术研究项目(GJJ14690)
关键词 精原细胞瘤 SALL4 OCT4 C-KIT 免疫组织化学 seminoma SALL4 OCT4 C-kit immunohistochemistry
  • 相关文献

参考文献4

二级参考文献44

  • 1丰有吉,沈铿.妇产科学.第2版.北京:人民卫生出版社,2011:127-128.
  • 2Ovarian cancer, five-year stage-specific relative survival rates (2004- 2008 ). J Natl Cancer Inst ,2011,103 : 1287.
  • 3Jemal A, Bray F, Center MM. Global cancer statistics. CA Cancer J Clin, 2011,61:69-90.
  • 4Bapat SA. Human ovarian cancer stem cells. Reproduction, 2010,140 : 33-41.
  • 5Ali S. Role of c-kit/SCF in cause and treatment of gastronintestinal sto- mal tumors(GIST). Gene ,2007,401:38-45.
  • 6Jin X,Jin X,Jung JE,et al. Cell surface Nestin is a biomarker for glioma stem cells. Biochem Biophys Res Commun,2013,19:496-501. [ Epub a- head of print].
  • 7Enache S, Arsene D, Iosif C, et al. Nestin and caveolin-1 in the diagnosis of GISTs. Rom J Morphol Embryo1,2012 ,53 :41-46.
  • 8Ohnuma A, Yoshida T, Takahashi N, et al. Malignant Leydig cell tumor with spindle-shaped ceils in a male CD-1 mouse. J Vet Med Sci ,2010, 72:661-664.
  • 9Akiyama M, Matsuda Y, Ishiwata T, et al. Inhibition of the stem cell marker nestin reduces tumor growth and invasion of malignant melano- ma. J Invest Dermatol,2013,133 : 1384-1387.
  • 10Ferrandina, G, Bonanno G, Picrclli L, et al. Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer,2008,18:506-514.

共引文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部